Sanofi has gained access to Biomunex Pharmaceuticals’ Plug-and-Play BiXAb platform through a licensing agreement.
Sanofi will use the platform to produce and optimise bi-specific and multi-specific antibody therapeutics, as well as develop antibody-based drugs.
Go deeper with GlobalData
The company will also conduct research, development, manufacturing and global commercialisation activities under the agreement.
Sanofi is expected to make an initial upfront payment to Biomunex, which will also be eligible to receive further clinical, regulatory and commercial milestone payments.
Sanofi develops medicines for human health, while Biomunex is a biopharmaceutical company focused on immuno-oncology treatments.
Both the companies involved in the deal are based in France.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataKnight Therapeutics has entered a licence agreement with Puma Biotechnology to commercialise Nerlynx (neratinib), which is targeted to treat early-stage HER2 overexpressed/amplified breast cancer in adults after adjuvant trastuzumab-based therapy.
Knight Therapeutics will have commercialisation rights and all future regulatory submissions for the drug in Canada. It has agreed to pay Puma Biotechnology up to $7.2m in upfront and milestone payments over the term of the deal, along with royalties on net sales of the drug in Canada.
Based in Canada, Knight Therapeutics is a speciality pharmaceutical company engaged in developing and licensing pharmaceutical products and medical devices, while Puma Biotechnology is a US-based development stage biopharmaceutical company focused on licensing and developing novel therapeutics.
Ascletis Pharma has entered a licensing agreement with Suzhou Alphamab to develop KN035, an investigational drug for the treatment of viral diseases.
The exclusive license gives Ascletis Pharma the rights to develop and commercialise the drug in Greater China. Suzhou Alphamab will receive an upfront cash payment along with development and commercial milestones with tiered royalties from future sales of the product. However, the manufacturing rights for the drug in Greater China will remain with Suzhou Alphamab.
Ascletis Pharma is a biotechnology company focused on developing anti-viral drugs, while Suzhou Alphamab is a biotechnology company engaged in developing and manufacturing biologics therapeutics.
Both the companies involved in the deal are based in China.
Medical Research Council (MRC) and the Agency for Medical Research and Development (AMED) in Japan are leading a team of medical researchers for the development of treatments for chronic degenerative and incurable diseases such as diabetes and heart disease.
As part of the collaboration, £10m will be allocated to a programme focused on regenerative medicine.
Businesses in the two countries will also jointly develop a new generation of assisted living products and services by leveraging artificial intelligence (AI) and robotics.
